Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Progression free survival rate
View:
Post by scarlet1967 on Jun 01, 2024 9:40am

Progression free survival rate

 

 

This bispecific antibody stops immunosuppression and blood supply process both responsible for progression of the cancer. The drug is now approved in combo therapy for cancer in China!

Different MOA but one could not ignore long term efficacy of cancer drugs and their place in the market as a stand alone drug or in combination with chemotherapy.

I thought it was interesting to bring this up as sudocetaxel zendusortide managed to stabilize the disease for long time.

https://ca.finance.yahoo.com/news/summit-shares-soar-lung-cancer-195343904.html

https://ca.finance.yahoo.com/news/ivonescimab-combination-chemotherapy-approved-china-230000301.html

Comment by Trogarzon on Jun 01, 2024 10:25am
Do we have something on their posters... something like those compelling news that could make us richer than 40 cents....
Comment by Trogarzon on Jun 01, 2024 2:51pm
I don't know why but I was under the impression that Marsolais was eager to tell us about new compelling data from Th1902 at ASCO.  I must have dreamed that because nothing posted about that yet. 
Comment by Qwerty54321 on Jun 01, 2024 10:55pm
I get ur point but you have to look at what other lung cancer drugs are capable of doing. It's the limited affects of other drugs that make this one look good (in lung cancer).  
Comment by Lee430 on Jun 02, 2024 1:32pm
Link to Thera's two ASOC abstracts. [url=https://https://meetings.asco.org/search?q=theratechnologies&filters=%7B%22contentTypeGroupLabel%22:%5B%7B%22key%22:%22General%20Information%22%7D,%7B%22key%22:%22Abstracts%20%26%20Presentations%22%7D,%7B%22key%22:%22Sessions%22%7D,%7B%22key%22:%22News%22%7D,%7B%22key%22:%22Member%20Blogs%22%7D,%7B%22key%22:%22Journals%22%7D,%7B%22key%22 ...more  
Comment by Lee430 on Jun 02, 2024 1:35pm
Hmm try again,  https://meetings.asco.org/search?q=theratechnologies&filters=%7B%22contentTypeGroupLabel%22:%5B%7B%22key%22:%22General%20Information%22%7D,%7B%22key%22:%22Abstracts%20%26%20Presentations%22%7D,%7B%22key%22:%22Sessions%22%7D,%7B%22key%22:%22News%22%7D,%7B%22key%22:%22Member%20Blogs%22%7D,%7B%22key%22:%22Journals%22%7D,%7B%22key%22:%22Guidelines%22%7D,%7B%22key%22 ...more  
Comment by Trogarzon on Jun 02, 2024 4:31pm
I read this and hobnestly i don't know what to make out of it and not much explanation for the the regular Joe in there.  I think we'll need sales to pay the dept and somthing else to climb out of thie sh..t hole. I don't even know if we can get tyhe 15M initial cost of Katana for that type of result.  As for te other 50M well  it's gone.
Comment by Trogarzon on Jun 03, 2024 5:54pm
Exciting no... the Russian way.. burned to the ground....
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities